Medicine Recommendations

Hypersalivation Unlicensed

Treatment of narcolepsy with or without cataplexy in adults.

Restless Legs Syndrome (as per LSCMMG Guidelines)

Vulvovaginal or vaginal atrophy in postmenopausal women having moderate to severe symptoms

with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (NICE TA317)

NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)

MHRA Drug Safety Update - Prasugrel: rare but serious hypersensitivity reactions 

Giant Cell Arteritis

Cluster Headache

Acute Gout (as per LSCMMG Guidelines)

Neuropathic pain

Prescribing of Pregabalin for the treatment of Generalised Anxiety Disorder (GAD)

Neuropathic pain (as per LSCMMG Guidelines)

Restless Legs Syndrome (off-licence as per LSCMMG Guidelines)

Nausea and vomiting in the last days of life

Schizophrenia and other psychoses, mania, short term management of severe anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Drug induced extrapyramidal side effects

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Progestogenic opposition of oestrogen HRT in women with an intact uterus

Short-term management of psychomotor agitation, agitation and restlessness in the elderly

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquillisation

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Anxiety